Severe community-acquired pneumonia: approach to therapy

Bibliography

• Current Estimates from National Health Interview Survey, 1996. Vital & Health Statistics Series 10(200). National Center for Health Statistics, 1999.
   Google Scholar
• JACKSON ML, NEUZIL KM, THOMPSON WW et al.: The burden of community-acquired pneumonia in seniors: results of a population-based study. Clin. Infect. Dis. (2004) 39(11):1642-1650.
   PubMed Web of Science ®Google Scholar
• BRITISH THORACIC SOCIETY STANDARDS OF CARE COMMITTEE: BTS guidelines for the management of community acquired pneumonia in adults. Thorax (2001) 56(Suppl. IV):1-64.
   PubMed Web of Science ®Google Scholar
• EWIG S, SCHAFER H, TORRES A: Severity assessment in community-acquired pneumonia. Eur. Respir. J. (2000) 16:1193-1201.
   PubMed Web of Science ®Google Scholar
• NEUHAUS T, EWIG S: Defining severe community-acquired pneumonia. Med. Clin. North Am. (2001) 85:1413-1425.
   PubMed Web of Science ®Google Scholar
• FINE MJ, AUBLE TE, YEALY DM et al.: A prediction rule to identify low-risk patients with community-acquired pneumonia. N. Engl. J. Med. (1997) 336(4):243-250.
   PubMed Web of Science ®Google Scholar
• NIEDERMAN MS, MANDELL LA, ANZUETO A et al.: Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am. J. Respir. Crit. Care Med. (2001) 163:1730-1754.
   PubMed Web of Science ®Google Scholar
• LIM WS, MACFARLANE JT, BOSWELL TC et al.: Study of community acquired pneumonia aetiology (SCAPA) in adults admitted to hospital: implications for management guidelines. Thorax (2001) 56:296-301
   PubMed Web of Science ®Google Scholar
• ROSON B, CARRATALA J, DORCA J et al.: Etiology, reasons for hospitalization, risk classes, and outcomes of community-acquired pneumonia in patients hospitalized on the basis of conventional admission criteria. Clin. Infect. Dis. (2001) 33:158-165.
   PubMed Web of Science ®Google Scholar
• NIEDERMAN MS, BASS JB, CAMPBELL GD et al.: Guidelines for the initial management of adults with community-acquired pneumonia: diagnosis, assessment of severity, and initial antimicrobial therapy. American Thoracic Society. Medical Section of the American Lung Association. Am. Rev. Respir. Dis. (1993) 148:1418-1426.
   PubMed Web of Science ®Google Scholar
• EWIG S, RUIZ M, MENSA J et al.: Severe community-acquired pneumonia. assessment of severity criteria. Am. J. Respir. Crit. Care Med. (1998) 158:1102-1108.
   PubMed Web of Science ®Google Scholar
• NEILL A, MARTIN I, WEIR R et al.: Community-acquired pneumonia: aetiology and usefulness of severity criteria on admission. Thorax (1996) 51:1010-1016.
   PubMed Web of Science ®Google Scholar
• LIM W, VAN DER EERDEN M, LAING R et al.: Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax (2003) 58:377-382.
   PubMed Web of Science ®Google Scholar
• BUISING KL, THURSKY KA, BLACK JF et al.: A prospective comparison of severity scores for identifying patients with severe community acquired pneumonia: reconsidering what is meant by severe pneumonia. Thorax (2006) 61(5):419-424.
   PubMed Web of Science ®Google Scholar
• ESPANA PP, CAPELASTEGUI A, GORORDO I et al.: Development and validation of a clinical prediction rule for severe community-acquired pneumonia. Am. J. Respir. Crit. Care Med. (2006) 174(11):1249-1256.
   PubMed Web of Science ®Google Scholar
• JACOBS MR, FELMINGHAM D, APPELBAUM PC, GRUNEBERG RN, The Alexander Project Group: The Alexander Project 1998-2000: susceptibility of pathogens isolated from community acquired respiratory tract infection to commonly used antimicrobial agents. J. Antimicrob. Chemother. (2003) 52:229-246.
   PubMed Web of Science ®Google Scholar
• TORRES A, SERRA-BATLLES J, FERRER A et al.: Severe community-acquired pneumonia. Epidemiology and prognostic factors. Am. Rev. Respir. Dis. (1991) 144:312-318.
   PubMed Web of Science ®Google Scholar
• PACHON J, PRADOS MD, CAPOTE F, CUELLO JA, GARNACHO J, VERANO A: Severe community-acquired pneumonia. etiology, prognosis, and treatment. Am. Rev. Respir. Dis. (1990) 142(2):369-373.
   PubMed Web of Science ®Google Scholar
• MOINE P, VERCKEN JB, CHEVRET S, CHASTANG C, GAJDOS P: Severe community-acquired pneumonia. Etiology, epidemiology, and prognosis factors. French study group for community-acquired pneumonia in the intensive care unit. Chest (1994) 105:1487-1495.
   PubMed Web of Science ®Google Scholar
• POTGIETER PD, JAMMOND JM: Etiology and diagnosis of pneumonia requiring ICU admission. Chest (1992) 101(1):199-203.
   PubMed Web of Science ®Google Scholar
• SORENSEN J, CEDERHOLM I, CARLSSON C: Pneumonia: a deadly disease despite intensive care treatment. Scand J. Infect. Dis. (1986) 18:329-335.
   PubMed Web of Science ®Google Scholar
• RELLO J, QUINTANA E, AUSINA V, NET A, PRATS G: A three-year study of severe community-acquired pneumonia with emphasis on outcome. Chest (1993) 103:232-235.
   PubMed Web of Science ®Google Scholar
• OLAECHEA PM, QUINTANA JM, GALLARDO MS, INSAUSTI J, MARAVI E, ALVAREZ B: A predictive model for the treatment approach to community-acquired pneumonia in patients needing ICU admission. Intensive Care Med. (1996) 22:1285-1287.
   PubMed Web of Science ®Google Scholar
• RELLO J, RODRIGUEZ R, JUBERT P, ALVAREZ B: Severe community-acquired pneumonia in the elderly: epidemiology and prognosis. Study group for severe community-acquired pneumonia. Clin. Infect. Dis. (1996) 23(4):723-728.
   PubMed Web of Science ®Google Scholar
• PAGANIN F, LILIENTHAL F, BOURDIN A et al.: Severe community-acquired pneumonia: assessment of microbial aetiology as mortality factor. Eur. Respir. J. (2004) 24:779-785.
   PubMed Web of Science ®Google Scholar
• RUIZ M, EWIG S, TORRES et al.: Severe community-acquired pneumonia. Risk factors and follow-up epidemiology. Am. J. Respir. Crit. Care Med. (1999) 160(3):923-929.
   PubMed Web of Science ®Google Scholar
• EL-SOLH AA, PAWAN S, RAMADAN F, DAVIES J: Etiology of severe pneumonia in the very elderly. Am. J. Respir. Crit. Care Med. (2001) 163(3):645-651.
   PubMed Web of Science ®Google Scholar
• LIEBERMAN D, SCHLAEFFER F, BOLDUR I et al.: Multiple pathogens in adult patients admitted with community-acquired pneumonia: a one-year prospective study of 346 consecutive patients. Thorax (1996) 51:179-184.
   PubMed Web of Science ®Google Scholar
• KAUPPINEN M, SAIKKU P: Pneumonia due to Chlamydia pneumoniae: Prevalence, clinical features, diagnosis, and treatment. Clin. Infect. Dis. (1995) 21:S244-S252.
   PubMed Web of Science ®Google Scholar
• GREENBERG SB: Viral pneumonia. Infect. Dis. Clin. North Am. (1991) 5:603-621.
   PubMedGoogle Scholar
• CHEN MZ, HSUEH PR, LEE LN, YU CJ, YANG PC, LUH KT: Severe community-acquired pneumonia due to Acinetobacter baumannii. Chest (2001) 120:1072- 1077.
   PubMed Web of Science ®Google Scholar
• FELDMAN C, ROSS S, MAHOMED A et al.: The aetiology of severe community-acquired pneumonia and its impact on initial, empiric, antimicrobial therapy. Respir. Med. (1995) 89:187-192.
   PubMed Web of Science ®Google Scholar
• DAHMASH N, CHOWDHURY M: Re-evaluation of pneumonia requiring admission to an intensive care unit: a prospective study. Thorax (1994) 49:71-76.
   PubMed Web of Science ®Google Scholar
• HUCHON G, WOODHEAD M: Management of adult community-acquired lower respiratory tract infections. Eur. Respir. Rev. (1998) 8:391-426.
   Google Scholar
• FRIDKIN SK, HAGEMAN JC, MORRISON M et al.: Methicillin-resistant Staphylococcus aureus disease in three communities. N. Engl. J. Med. (2005) 352:1436-1444.
   PubMed Web of Science ®Google Scholar
• HAGEMAN JC, UYEKI TM, FRANCIS JS et al.: Severe community-acquired pneumonia due to Staphylococcus aureus, 2003-04 influenza season. Emerg. Infect. Dis. (2006) 12(6):894-899.
   PubMed Web of Science ®Google Scholar
• NAIMI TS, LEDELL KH, COMO-SABIETTI K et al.: Comparison of community-acquired and health care-associated methicillin-resistant Staphylococcus aureus infection. JAMA (2003) 290:2976-2984.
   PubMed Web of Science ®Google Scholar
• CHIOU CC, LIU YC, HUANG TS et al.: Extremely high prevalence of nasopharyngeal carriage of penicillin-resistant Streptococcus pneumoniae among children in Kaohsiung, Taiwan. J. Clin. Microbiol. (1998) 36:1933-1937.
   PubMed Web of Science ®Google Scholar
• CLAVO-SANCHEZ A, GIRON-GONZALEZ J, LOPEZ-PRIETO D et al.: Multivariate analysis of risk factors for infection due to penicillin resistant and multidrug resistant streptococcus pneumoniae: a multicenter study. Clin. Infect. Dis. (1997) 24:1052-1059.
   PubMed Web of Science ®Google Scholar
• STRAUS WL, QAZI SA, KUNDI Z et al.: Antimicrobial resistance and clinical effectiveness of co-trimoxazole versus amoxycillin for pneumonia among children in Pakistan: randomized controlled trial Pakistan Co-trimoxazole Study Group. Lancet (1998) 352:270-274.
   PubMed Web of Science ®Google Scholar
• ASPA J, RAJAS O, RODRIGUEZ DE CASTRO F et al.: Drug-resistant pneumococcal pneumonia: clinical relevance and related factors. Pneumococcal Pneumonia in Spain Study Group. Clin. Infect. Dis. (2004) 38:787-798.
   PubMed Web of Science ®Google Scholar
• LEROY O, SANTRE C, BEUSCART C: A 5-year study of severe community-acquired pneumonia with emphasis on prognosis in patients admitted to an ICU. Intensive Care Med. (1995) 21:24-31.
   PubMed Web of Science ®Google Scholar
• KOLLEF M, SHERMAN G, WARD S et al.: Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients. Chest (1999) 115:462-474.
   PubMed Web of Science ®Google Scholar
• PASCUAL F, MATTHAY M, BACCHETTI P et al.: Assessment of prognosis in patients with community-acquired pneumonia who require mechanical ventilation. Chest (2000) 117:503-512.
   PubMed Web of Science ®Google Scholar
• GARCIA-ORDONEZ M, GARCIA-JIMENEZ J, PAEZ F et al.: Clinical aspects and prognostic factors in elderly patients hospitalized for community-acquired pneumonia. Eur. J. Clin. Microbiol. Infect. Dis. (2001) 20:14-19.
   PubMed Web of Science ®Google Scholar
• BARTLETT J, BREIMAN R, MANDELL L et al.: Community-acquired pneumonia in adults: guidelines for management; The Infectious Diseases Society of America. Clin. Infect. Dis. (1998) 26:811-838.
   PubMed Web of Science ®Google Scholar
• OOSTERHEERT JJ, BONTEN MJ, HAK E, SCHNEIDER MM, HOEPELMAN IM: How good is the evidence for the recommended empirical antimicrobial treatment of patients hospitalized because of community-acquired pneumonia? A systematic review. J. Antimicrob. Chemother. (2003) 52:555-563.
   PubMed Web of Science ®Google Scholar
• KAHN KL, ROGERS WH, RUBENSTEIN LV et al.: Measuring quality of care with explicit process criteria before and after implementation of the DRG-based prospective payment system. JAMA (1990) 264(15):1969-1973.
   PubMed Web of Science ®Google Scholar
• MCGARVEY RN, HARPER JJ. Pneumonia mortality reduction and quality improvement in a community hospital. Qual Rev Bull (1993) 19:124-130.
   PubMedGoogle Scholar
• MEEHAN T, FINE M, KRUMHOLZ H et al.: Quality of care, process, and outcomes in elderly patients with pneumonia. JAMA (1997) 278:2080-2084.
   PubMed Web of Science ®Google Scholar
• HOUCK P, BRATZLER D, NSA W, MA A, BARTLETT JG: Timing of antibiotic administration and outcomes for Medicare patients hospitalized with community-acquired pneumonia. Arch. Intern. Med. (2004) 164:637-644.
   PubMedGoogle Scholar
• BATTLEMAN DS, CALLAHAN M, THALER HT: Rapid antibiotic delivery and appropriate antibiotic selection reduce length of hospital stay of patients with community-acquired pneumonia. Arch. Intern. Med. (2002) 162:682-688.
   PubMed Web of Science ®Google Scholar
• BENENSON R, MAGALSKI A, CAVANAUGH S, WILLIAMS E: Effects of a pneumonia clinical pathway on time to antibiotic treatment, length of stay, and mortality. Acad. Emerg. Med. (1999) 6:1243-1248.
   PubMed Web of Science ®Google Scholar
• MARRIE TJ, WU L: Factors influencing in-hospital mortality in community acquired pneumonia: a prospective study of patients not initially admitted to the ICU. Chest (2005) 127:1260-1270.
   PubMed Web of Science ®Google Scholar
• SILBER SH, GARRETT C, SINGH R et al.: Early administration of antibiotics does not shorten time to clinical stability in patients with moderate-to-severe community acquired pneumonia. Chest (2003) 124:1798-1804.
   PubMed Web of Science ®Google Scholar
• Guidelines for the management of community-acquired pneumonia in adults admitted to hospital. The British Thoracic Society. Br J Hosp. Med (1993) 49:346-350.
   PubMed Web of Science ®Google Scholar
• MANDELL LA, NIEDERMAN MS: Antimicrobial treatment of community-acquired pneumonia in adults: a conference report. Canadian Community-Acquired Pneumonia Consensus Conference Group. Can J. Infect. Dis. (1993) 4:25.
   PubMedGoogle Scholar
• BARTLETT JG, BREIMAN RF, MANDELL LA, FILE TM Jr: Community-acquired pneumonia in adults: guidelines for management. Infectious Diseases Society of America. Clin. Infect. Dis. (1998) 26:811-838.
   PubMed Web of Science ®Google Scholar
• BARTLETT JG, DOWELL SF, MANDELL LA, FILE TM Jr, MUSHER DM, FINE MJ: Practice guidelines for the management of community-acquired pneumonia in adults. Infectious Diseases Society of America. Clin. Infect. Dis. (2000) 31:347-382.
   PubMed Web of Science ®Google Scholar
• MANDELL LA, BARTLETT JG, DOWELL SF, FILE TM JR, MUSHER DM, WHITNEY C: Infectious Diseases Society of America. Update of practice guidelines for the management of community-acquired pneumonia in immunocompetent adults. Clin. Infect. Dis. (2003) 37:1405-1433.
   PubMed Web of Science ®Google Scholar
• DEAN NC, BATEMAN KA, DONNELLY SM, SILVER MP, SNOW GL, HALE D: Improved clinical outcomes with utilization of a community-acquired pneumonia guideline. Chest (2006) 130:794-799.
   PubMed Web of Science ®Google Scholar
• MORTENSEN EM, RESTREPO M, ANZUETO A, PUGH J: Effects of guideline-concordant antimicrobial therapy on mortality among patients with community-acquired pneumonia. Am. J. Med. (2004) 117:726-731.
   PubMed Web of Science ®Google Scholar
• FREI CR, RESTREPO MI, MORTENSEN EM, BURGESS DS: Impact of guideline-concordant empiric therapy in community-acquired pneumonia. Am. J. Med. (2006) 119:865-871.
   PubMed Web of Science ®Google Scholar
• MALONE DC, SHABAN HM: Adherence to ATS guidelines for hospitalized patients with community-acquired pneumonia. Ann. Pharmacother. (2001) 35:1180-1185.
   PubMed Web of Science ®Google Scholar
• MUFSON MA, STANEK RJ: Bacteremic pneumococcal pneumonia in one American City: a 20-year longitudinal study, 1978-1997. Am. J. Med. (1999) 107(Suppl. 1A):34S-43S.
   PubMed Web of Science ®Google Scholar
• WATERER GW, SOMES GW, WUNDERINK RG: Monotherapy may be suboptimal for severe bacteremic pneumococcal pneumonia. Arch. Intern. Med. (2001) 161:1837-842.
   PubMedGoogle Scholar
• MARTINEZ JA, HORCAJADA JP, ALMELA M et al.: Addition of a macrolide to a β-lactam-based empirical antibiotic regimen is associated with lower in-hospital mortality for patients with bacteremic pneumococcal pneumonia. Clin. Infect. Dis. (2003) 36:389-395.
   PubMed Web of Science ®Google Scholar
• BADDOUR LM, YU VL, KLUGMAN KP et al.: Combination antibiotic therapy lowers mortality among severely ill patients with pneumococcal bacteremia. Am. J. Respir. Crit. Care Med. (2004) 170:440-444.
   PubMed Web of Science ®Google Scholar
• WEISS K, LOW DE, CORTES L et al.: Clinical characteristics at initial presentation and impact of dual therapy on the outcome of bacteremic Streptococcus pneumoniae pneumonia in adults. Can. Respir. J. (2004) 11:589-593.
   PubMedGoogle Scholar
• HARBARTH S, GARBINO J, PUGIN J, ROMAND JA, PITTET D: Lack of effect of combination antibiotic therapy on mortality in patients with pneumococcal sepsis. Eur. J. Clin. Microbiol. Infect. Dis. (2005) 24:688-690.
   PubMed Web of Science ®Google Scholar
• GARCIA-VAZQUEZ E, MENSA J, MARTINEZ JA et al.: Lower mortality among patients with community-acquired pneumonia treated with a macrolide plus a β-lactam agent alone. Eur. J. Clin. Microbiol. Infect. Dis. (2005) 24:190-195.
   PubMed Web of Science ®Google Scholar
• MORTENSEN EM, RESTREPO MI, ANZUETO A, PUGH J: The impact of empiric antimicrobial therapy with a β-lactam and fluoroquinolone on mortality for patients hospitalized with severe pneumonia. Crit. Care (2006) 10:R8.
   Web of Science ®Google Scholar
• RESTREPO M, MORTENSEN E, ANZUETO A et al.: Mortality in monotherapy versus combination therapy in severe community-acquired pneumonia: a systematic review. Chest (2003) 124:190S.
   Web of Science ®Google Scholar
• PATERSON D: ‘Collateral damage’ from cephalosporin or quinolone antibiotic therapy. Clin. Infect. Dis. (2004) 38:S341-S345.
   PubMed Web of Science ®Google Scholar
• TAN MJ, TAN JS, FILE TM JR: Legionnaires disease with bacteremic coinfection. Clin. Infect. Dis. (2002) 35:533-539.
   PubMed Web of Science ®Google Scholar
• KAUPPINEN MT, SAIKKU P, KUJALA P et al.: Clinical picture of community acquired Chlamydia pneumoniae pneumonia requiring hospital treatment: a comparison between chlamydial and pneumococcal pneumonia. Thorax (1996) 51:185-189.
   PubMed Web of Science ®Google Scholar
• GLEASON PP, MEEHAN TP, FINE JM et al.: Associations between initial antimicrobial therapy and medical outcomes for hospitalized elderly patients with pneumonia. Arch. Internal Med. (1999) 159:2562-2572.
   PubMed Web of Science ®Google Scholar
• METLAY JP, SINGER DE: Outcomes in lower respiratory tract infections and the impact of antimicrobial drug resistance. Clin. Microbiol. Infect. (2002) 8(Suppl. 2):1-11.
   PubMed Web of Science ®Google Scholar
• CUNHA B: Doxycycline for community-acquired pneumonia [letter]. Clin. Infect. Dis. (2003) 37:870.
   PubMed Web of Science ®Google Scholar
• BHAVNANI SM, HAMMEL JP, JONES RN et al.: Relationship between increased levofloxacin use and decreased susceptibility of Streptococcus pneumoniae in the United States. Diagn. Microbiol. Infect. Dis. (2005) 51:31-37.
   PubMed Web of Science ®Google Scholar
• KHAIR OA, DEVALIA JL, ABDELAZIZ MM, SAPSFORD RJ, DAVIES RJ: Effect of erythromycin on Haemophilus influenzae endotoxin-induced release of IL-6, IL-8, and sICAM-1 by cultured human bronchial epithelial cells. Eur. Respir. J. (1995) 8:1451-1457.
   PubMed Web of Science ®Google Scholar
• SUGIYAMA Y, YANAGISAWA K, TOMINAGA SI, KITAMURA S: Effects of long-term administration of erythromycin on cytokine production in rat alveolar macrophages. Eur. Respir. J. (1999) 14:1113-1116.
   PubMed Web of Science ®Google Scholar
• OOSTERHEERT JJ, BONTEN MJ, SCHNEIDER MM et al.: Effectiveness of early switch from intravenous to oral antibiotics in severe community acquired pneumonia: multicenter randomized trial. Br. Med. J. (2006) 333:1193.
   PubMed Web of Science ®Google Scholar
• AMBROSINO N, FOGLIO K, RUBINI F et al.: Non-invasive mechanical ventilation in acute respiratory failure due to chronic obstructive pulmonary disease: correlates for success. Thorax (1995) 50:755-757.
   PubMed Web of Science ®Google Scholar
• CONFALONIERI M, POTENA A, CARBONE G et al.: Acute respiratory failure in patients with severe community-acquired pneumonia: a prospective randomized evaluation of noninvasive ventilation. Am. J. Respir. Crit. Care Med. (1999) 160:1585-1591.
   PubMed Web of Science ®Google Scholar
• JOLLIET P, ABAJO B, PASQUINA P, CHEVROLET JC: Non-invasive pressure support ventilation in severe community-acquired pneumonia. Intensive Care Med. (2001) 27(5):812-821.
   PubMed Web of Science ®Google Scholar
• WAGNER HN, BENNETT IL JR, LASAGNA L et al.: The effect of hydrocortisone upon the course of pneumococcal pneumonia treated with penicillin. Bull Johns Hopkins Hosp. (1956) 98:197-215.
   PubMedGoogle Scholar
• Cooperative Study Group. The effectiveness of hydrocortisone in the management of severe infections. JAMA (1963) 183:462-465.
   Web of Science ®Google Scholar
• MARIK P, KRAUS P, SRIBANTE J et al.: Hydrocortisone and tumor necrosis factor in severe community-acquired pneumonia: a randomized controlled study. Chest (1993) 104:389-392.
   PubMed Web of Science ®Google Scholar
• MER M, RICHARDS GA: Corticosteroids in life-threatening varicella pneumonia. Chest (1998) 114:426-431.
   PubMed Web of Science ®Google Scholar
• MONTON C, EWIG S, TORRES A et al.: Role of glucocorticoids on inflammatory response in nonimmunosuppressed patients with pneumonia: a pilot study. Eur. Respir. J. (1999) 14:218-220.
   PubMed Web of Science ®Google Scholar
• CONFALONIERI M, URBINO R, POTENA A et al.: Hydrocortisone infusion for severe community-acquired pneumonia: a preliminary randomized study. Am. J. Respir. Crit. Care Med. (2005) 171:242-248.
   PubMed Web of Science ®Google Scholar
• SALLUH JI, VERDEAL JC, MELLO GW et al.: Cortisol levels in patients with severe community-acquired pneumonia. Intensive Care Med. (2006) 32:595-598.
   PubMed Web of Science ®Google Scholar
• BERNARD GR, VINCENT JL, LATERRE P et al. : Efficacy and safety of recombinant human activated protein C for severe sepsis. N. Engl. J. Med. (2001) 344:699-709.
   PubMed Web of Science ®Google Scholar
• LATERRE PF, GARBER G, LEVY H et al.: Severe community-acquired pneumonia as a cause of severe sepsis: data from the PROWESS study. Crit. Care Med. (2005) 33:952-961.
   PubMed Web of Science ®Google Scholar
• DHAINAUT JF, LATERRE PF, JANES JM et al.: Drotrecogin α (activated) in the treatment of severe sepsis patients with multiple-organ dysfunction: data from the PROWESS trial. Intensive Care Med. (2003) 29:894-903.
   PubMed Web of Science ®Google Scholar
• ABRAHAM E, LATERRE PF, GARG R et al.: Administration of Drotrecogin α (Activated) in Early Stage Severe Sepsis (ADDRESS) Study Group. Drotrecogin α (activated) for adults with severe sepsis and a low risk of death. N. Engl. J. Med. (2005) 353(13):1332-1341.
   PubMed Web of Science ®Google Scholar
• PITTAS GP, SIEGEL RD, LAU J: Insulin therapy for critically ill hospitalized patients. Arch Int Med (2004) 164:2005-2011.
   PubMedGoogle Scholar
• VAN DEN BERGHE G, WOUTERS P, WEEKERS F et al.: Intensive insulin therapy in critically ill patients. N. Engl. J. Med. (2001) 345:1359-1367.
   PubMed Web of Science ®Google Scholar
• VAN DEN BERGHE G, WILMER A, HERMANS G et al.: Intensive insulin therapy in the medical ICU. N. Engl. J. Med. (2006) 354:449-461.
   PubMed Web of Science ®Google Scholar
• NELSON S, HEYDER A, STONE J et al.: A randomized controlled trial of filgrastim for the treatment of hospitalized patients with multilobar pneumonia. J. Infect. Dis. (2000) 182:970-973.
   PubMed Web of Science ®Google Scholar
• ROOT RK, LODATO RF, PATRICK W et al.: Multicenter, double-blind, placebo-controlled study of the use of filgrastim in patients hospitalized with pneumonia and severe sepsis. Crit. Care Med. (2003) 31:367-373.
   PubMed Web of Science ®Google Scholar
• MCKENNA PH, NELSON S, ANDERSON J: Filgrastim enhances ciprofloxacin uptake and bactericidal activity of human neutrophils in vitro. Am. J. Respir. Crit. Care Med. (1996) 153:A535.
   PubMed Web of Science ®Google Scholar
• CHENG AC, STEPHENS DP, CURRIE BJ: Granulocyte-colony stimulating factor (G-CSF) as an adjunct to antibiotics in the treatment of pneumonia in adults. Update of Cochrane Database Syst. Rev. (2003) (4):CD004400.
   Google Scholar
• SCHENTAG JJ, NIX DE, FORREST A et al.: AUIC – the universal parameter within the constraint of a reasonable dosing interval. Ann. Pharmacother. (1996) 30(9):1029-1031.
   PubMed Web of Science ®Google Scholar
• BERGERON MG, OUELLETTE M: Preventing antibiotic resistance through rapid genotypic identification of bacteria and of their antibiotic resistance genes in the clinical microbiology laboratory. J. Clin. Microbiol. (1998) 36(8):2169-2172.
   PubMed Web of Science ®Google Scholar
• BERGERON MG, OUELLETTE M: Preventing antibiotic resistance using rapid DNA-based diagnostic tests. Infect Control Hosp. Epidemiol (1998) 19(8):560-564.
   PubMed Web of Science ®Google Scholar
• HANCOCK RE: The role of fundamental research and biotechnology in finding solutions to the global problem of antibiotic resistance. Clin. Infect. Dis. (1997) 24(Suppl. 1):148S-150S
   PubMed Web of Science ®Google Scholar
• EL MOUSSAOUI R, DE BORGIE C, VAN DEN BROEK P et al.: Effectiveness of discontinuing antibiotic treatment after three days versus eight days in mild to moderate-severe community acquired pneumonia: randomized, double-blind study. Br. Med. J. (2006) 332:1355-1358.
   PubMed Web of Science ®Google Scholar
• WATERER G, QUASNEY M, CANTOR R et al.: Septic shock and respiratory failure in community-acquired pneumonia have different TNF polymorphism associations. Am. J. Respir. Crit. Care Med. (2001) 163:1599-1604.
   PubMed Web of Science ®Google Scholar
• WATERER G, QUASNEY M, CANTOR R et al.: Increased risk of death from community-acquired pneumonia associated with the A allele of the TNF-α 238 polymorphism. Am. J. Respir. Crit. Care Med. (2001) 163:A380.
   Web of Science ®Google Scholar